Loading
NASDAQHealthcareBiotechnology
Latest quote
$10.96
−$0.34 · -3.01%
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Previous close
$10.96
−$0.34 · -3.01%
Regular session · ET · Market data may be delayed.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Day range
Current $10.96
52-week range
Current $10.96
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
56
Fair Value
Sentiment
64
Bullish
Risk
44
Elevated Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Day range
Current $10.96
52-week range
Current $10.96
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44.64M USD | 47.54M USD | 21.25M USD | 1.54M USD | — |
| Cost of goods sold | 3.76M USD | 3.18M USD | 1.26M USD | 86K USD | — |
| Gross profit | 40.88M USD | 44.35M USD | 19.99M USD | 1.45M USD | — |
| Research and development | 250K USD | 307K USD | 56K USD | 3.53M USD | 4.98M USD |
| Selling, general, and administrative | 46.91M USD | 41.48M USD | 32.71M USD | 20.51M USD | 12.24M USD |
| Operating expenses | 47.22M USD | 41.88M USD | 33.05M USD | 24.19M USD | 17.22M USD |
| Interest income | 787K USD | 1.59M USD | 441K USD | 195K USD | 54K USD |
| Interest expense | 2.08M USD | 4.07M USD | 3.39M USD | 978K USD | 126K USD |
| Depreciation and amortization | 103K USD | 800K USD | 287K USD | 149K USD | 16K USD |
| Operating income | −6.35M USD | 2.48M USD | −13.06M USD | −22.74M USD | −17.22M USD |
| Net income | −9.74M USD | −436K USD | −16.05M USD | −23.71M USD | −17.35M USD |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.8M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Russell 2000 ETFVTWO1.56M0.01%17.4B USD0.06%$116.76+0.36%
Vanguard Russell 2000 Growth ETFVTWG304.56K0.02%1.7B USD0.06%$268.4+0.57%
Global X - Russell 2000 ETFRSSL151.26K0.01%1.47B USD0.08%$113.11+0.42%
Vanguard Russell 3000 ETFVTHR20.05K0.00%6.1B USD0.06%$337.14+0.87%
ProShares - UltraPro Russell2000URTY12.52K0.00%294.16M USD1.08%$75.31+1.01%
ProShares - Ultra Russell2000UWM9.6K0.00%231.17M USD1.07%$61.28+0.74%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM6.47K0.00%697.71M USD0.89%$58.53+0.60%Vanguard Morningstar Total Stock Market ETFVTIVanguard Russell 2000 ETFVTWOVanguard Russell 2000 Growth ETFVTWGGlobal X - Russell 2000 ETFRSSLVanguard Russell 3000 ETFVTHRProShares - UltraPro Russell2000URTYProShares - Ultra Russell2000UWMMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
